NanoString Highlights Spatial Biology Research from the 2021 American Association of Cancer Research (AACR) Conference

Rhea-AI Summary

NanoString Technologies (NASDAQ: NSTG) announced the presentation highlights of spatial biology research at the AACR 2021 meeting to be held from April 10-15, 2021. The GeoMx® Digital Spatial Profiler (DSP) will be featured in eight abstracts, showcasing its capability in profiling RNA and proteins in breast cancer research. Notably, four abstracts will be presented by the GeoMx Breast Cancer Consortium, aiming to create a comprehensive database of novel biomarkers. The DSP has been referenced in numerous publications and provides significant insights into tumor microenvironments and treatment responses.

Positive

• Eight abstracts featuring the GeoMx DSP will be presented at AACR 2021, emphasizing ongoing research.
• The GeoMx DSP has been cited in over 45 peer-reviewed publications, showcasing its broad utility.
• The research may lead to advancements in precision medicine for breast cancer, improving therapeutic strategies.

Negative

• None.

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the highlights of spatial biology abstracts that will be presented at the 2021 meeting of the American Association of Cancer Research (AACR), which will be held virtually from April 10 - 15, 2021.

The GeoMx® Digital Spatial Profiler (DSP) enables researchers to characterize tissue morphology to rapidly and quantitatively profile RNA and proteins. To date, NanoString and its collaborators have presented DSP data in dozens of abstracts at major scientific meetings and more than 45 peer-reviewed publications, demonstrating DSP’s utility to address a wide range of biological questions in formalin-fixed paraffin-embedded (FFPE) and frozen tissues. At AACR 2021, eight abstracts that used GeoMx DSP will be presented during the poster session on Saturday, April 10.

Four of the eight abstracts will be presented by investigators from the GeoMx Breast Cancer Consortium (GBCC), an international network of breast cancer researchers. Their goal is to apply innovative approaches and decipher the spatial context of breast cancer to develop a comprehensive atlas and database of novel biomarkers for the disease.

GBCC Abstracts

Poster 2718: Digital spatial profiling in HER2 positive breast cancer: The road to precision medicine

In this work, the GeoMx DSP was used to profile 71 protein targets and gene expression profiling was done using NanoString's nCounter PanCancer IO360 assay for primary and metastatic tissues from human epidermal growth factor 2 positive (HER2+) breast cancer (BC) patients. A detailed characterization of carefully chosen immune cold, warm and hot regions of interest (ROI) in the tumor and tumor immune microenvironment of (HER2+) of these samples established that primary tumors had a higher number of immune cells than the metastatic sites. These findings, therefore, suggest that immunotherapy in early-stage BC could be more effective than in advanced BC.

Poster 2701: Molecular profiling to assess the immune response to neoadjuvant SABR in early breast cancer

NanoString's Human PanCancer immune profiling panel was used to assess the impact of localized radiotherapy to elicit an immune response in primary breast carcinomas before lumpectomy. They analyzed 25 patient samples for low-risk primary breast carcinomas from the SIGNAL 2.0 clinical trial using the GeoMx DSP platform, pre, and post stereotactic body radiation therapy (SBRT). Significant differences were found in the gene expression patterns in the immune microenvironment gene expression patterns and cellular composition after radiotherapy, demonstrating that SBRT treatment indeed evokes an immune response, increasing the innate immune response.

Poster 2698: Spatial gene expression profiling in breast cancer

Transcriptome profiling was performed for a cohort of breast cancer lumpectomies using the Cancer Transcriptomic Atlas (CTA) assay on the GeoMx DSP platform. Analysis of 60 patient samples revealed region-specific heterogeneity in unifocal and multifocal cancer tumors. This study demonstrates and establishes the importance of interactions between immune and tumor cells in the tumor microenvironment and the need to develop a strategy to stratify patients to available targeted therapies.

Poster 2726: Characterization of immune microenvironment and heterogeneity in breast cancer subtypes

In this work, the immune microenvironment of Luminal A, Luminal B, Basal, and HER2 tumor subtypes in a cohort of earl

FAQ

What will NanoString present at AACR 2021?

NanoString will present eight abstracts highlighting the use of the GeoMx Digital Spatial Profiler at the AACR 2021 meeting.

What is the significance of the GeoMx DSP in cancer research?

The GeoMx DSP allows for detailed profiling of RNA and proteins, aiding in the understanding of tumor microenvironments.

When is the AACR 2021 meeting?

The AACR 2021 meeting is scheduled for April 10-15, 2021.

How many peer-reviewed publications reference the GeoMx DSP?

The GeoMx DSP has been referenced in more than 45 peer-reviewed publications.

Who is involved in the research presented by NanoString at AACR 2021?

The GeoMx Breast Cancer Consortium, an international network of breast cancer researchers, will present four of the eight abstracts.